Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in the United States

2019 ◽  
Vol 35 (3) ◽  
pp. 375-381 ◽  
Author(s):  
David Henry ◽  
Roger von Moos ◽  
Jean-Jacques Body ◽  
Alex Rider ◽  
Jonathan De Courcy ◽  
...  
Keyword(s):  
Breast Cancer ◽  
United States ◽  
Advanced Breast Cancer ◽  
Bone Metastases ◽  
The United States ◽  
Treatment Patterns ◽  
Advanced Breast ◽  
Targeted Agent ◽  
The Impact ◽  
Agent Treatment

Physician treatment preferences for HR+/HER2- advanced breast cancer patients: A survey of community oncology practices in the United States.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. e11517-e11517
Author(s):  
Eric Qiong Wu ◽  
Yanni Hao ◽  
James E. Signorovitch ◽  
Peggy L. Lin ◽  
Alexander R. Macalalad ◽  
...  
Keyword(s):  
Breast Cancer ◽  
United States ◽  
Advanced Breast Cancer ◽  
Cancer Patients ◽  
The United States ◽  
Advanced Breast ◽  
Treatment Preferences ◽  
Breast Cancer Patients ◽  
Community Oncology

scholarly journals BRCA status, treatment patterns and outcomes in HER2- advanced breast cancer (ABC): A multi-country real-world study

2019 ◽  
Vol 30 ◽  
pp. iii51-iii52
Author(s):  
A. Niyazov ◽  
R.G.W. Quek ◽  
K. Lewis ◽  
J. Kemp ◽  
A. Rider
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Real World ◽  
Treatment Patterns ◽  
Advanced Breast

Plasma ESR1 Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer

2016 ◽  
Vol 34 (25) ◽  
pp. 2961-2968 ◽  
Author(s):  
Charlotte Fribbens ◽  
Ben O’Leary ◽  
Lucy Kilburn ◽  
Sarah Hrebien ◽  
Isaac Garcia-Murillas ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Advanced Breast Cancer ◽  
Metastatic Breast ◽  
Advanced Breast ◽  
Phase Iii ◽  
Wild Type ◽  
Estrogen Receptor Positive ◽  
Esr1 Mutations ◽  
The Impact

Purpose ESR1 mutations are selected by prior aromatase inhibitor (AI) therapy in advanced breast cancer. We assessed the impact of ESR1 mutations on sensitivity to standard therapies in two phase III randomized trials that represent the development of the current standard therapy for estrogen receptor–positive advanced breast cancer. Materials and Methods In a prospective-retrospective analysis, we assessed ESR1 mutations in available archived baseline plasma from the SoFEA (Study of Faslodex Versus Exemestane With or Without Arimidex) trial, which compared exemestane with fulvestrant-containing regimens in patients with prior sensitivity to nonsteroidal AI and in baseline plasma from the PALOMA3 (Palbociclib Combined With Fulvestrant in Hormone Receptor–Positive HER2-Negative Metastatic Breast Cancer After Endocrine Failure) trial, which compared fulvestrant plus placebo with fulvestrant plus palbociclib in patients with progression after receiving prior endocrine therapy. ESR1 mutations were analyzed by multiplex digital polymerase chain reaction. Results In SoFEA, ESR1 mutations were found in 39.1% of patients (63 of 161), of whom 49.1% (27 of 55) were polyclonal, with rates of mutation detection unaffected by delays in processing of archival plasma. Patients with ESR1 mutations had improved progression-free survival (PFS) after taking fulvestrant (n = 45) compared with exemestane (n = 18; hazard ratio [HR], 0.52; 95% CI, 0.30 to 0.92; P = .02), whereas patients with wild-type ESR1 had similar PFS after receiving either treatment (HR, 1.07; 95% CI, 0.68 to 1.67; P = .77). In PALOMA3, ESR1 mutations were found in the plasma of 25.3% of patients (91 of 360), of whom 28.6% (26 of 91) were polyclonal, with mutations associated with acquired resistance to prior AI. Fulvestrant plus palbociclib improved PFS compared with fulvestrant plus placebo in both ESR1 mutant (HR, 0.43; 95% CI, 0.25 to 0.74; P = .002) and ESR1 wild-type patients (HR, 0.49; 95% CI, 0.35 to 0.70; P < .001). Conclusion ESR1 mutation analysis in plasma after progression after prior AI therapy may help direct choice of further endocrine-based therapy. Additional confirmatory studies are required.

Sign in / Sign up

Export Citation Format

Share Document